Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Carfilzomib公司 来那度胺 达拉图穆马 多发性骨髓瘤 医学 微小残留病 自体干细胞移植 肿瘤科 内科学 移植 中性粒细胞减少症 人口 外科 临床终点 临床试验 化疗 骨髓 环境卫生
作者
Cyrille Touzeau,Aurore Perrot,Cyrille Hulin,Salomon Manier,Margaret Macro,Marie‐Lorraine Chrétien,Lionel Karlin,Martine Escoffre‐Barbe,Caroline Jacquet,Mourad Tiab,Xavier P Leleu,Hervé Avet‐Loiseau,Alexandra Jobert,Lucie Planche,Jill Corre,Philippe Moreau
出处
期刊:Blood [Elsevier BV]
卷期号:143 (20): 2029-2036 被引量:77
标识
DOI:10.1182/blood.2023023597
摘要

ABSTRACT: High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple myeloma (NDMM), and dedicated studies should address this difficult-to-treat population. The phase 2 study 2018-04 from the Intergroupe Francophone du Myelome evaluated feasibility of an intensive strategy with quadruplet induction and consolidation plus tandem transplant in HR transplant-eligible (TE) NDMM. HR cytogenetics were defined by presence of del(17p), t(4;14), and/or t(14;16). Treatment consisted of daratumumab-carfilzomib-lenalidomide-dexamethasone (D-KRd) induction, autologous stem cell transplantation (ASCT), D-KRd consolidation, second ASCT, and daratumumab-lenalidomide maintenance. The primary end point was feasibility. Fifty patients with previously untreated NDMM were included. Median age was 57. Del(17p), t(4;14), and t(14;16) were found in 40%, 52%, and 20% of patients, respectively. At data cutoff, the study met the primary end point with 36 patients completing second transplant. Twenty patients discontinued the study due to stem cell collection failure (n = 8), disease progression (n = 7), adverse event (n = 4), or consent withdrawal (n = 1). Grade 3 to 4 D-KRd induction/consolidation-related adverse events (>5% of patients) were neutropenia (39%), anemia (12%), thrombocytopenia (7%), and infection (6%). The overall response rate was 100% for patients completing second transplant, including 81% complete response. Premaintenance minimal residual disease (MRD) negativity rate (10-6) was 94%. After a median follow-up of 33 months, the 30-month progression-free survival (PFS) and overall survival were 80% and 91%, respectively. In conclusion, D-KRd with tandem transplant is feasible in patients with HR TE-NDMM and resulted in high response rates and PFS. This trial was registered at www.clinicaltrials.gov as #NCT03606577.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
魏伯安发布了新的文献求助10
2秒前
耦23发布了新的文献求助10
3秒前
Magnolia_Yun发布了新的文献求助30
3秒前
星辰大海的应助被酷炫笑柳采纳,获得10
4秒前
six完成签到,获得积分10
5秒前
6秒前
6秒前
7秒前
华仔的应助被茉云采纳,获得10
8秒前
8秒前
个性青寒完成签到,获得积分10
9秒前
9秒前
9秒前
10秒前
11秒前
烟花的应助被sghsh采纳,获得10
11秒前
saflgf发布了新的文献求助10
11秒前
烟花的应助被XX采纳,获得10
12秒前
12秒前
13秒前
null发布了新的文献求助10
13秒前
CodeCraft的应助被想人陪的蚂蚁采纳,获得30
14秒前
万能图书馆的应助被CITY111119采纳,获得50
14秒前
大药瓶子发布了新的文献求助10
14秒前
火星上的寄凡完成签到,获得积分10
15秒前
15秒前
15秒前
15秒前
Qin发布了新的文献求助30
16秒前
学术智子发布了新的文献求助10
17秒前
18秒前
背后的千柳完成签到,获得积分10
18秒前
小陈爱学习完成签到,获得积分10
18秒前
Tuniverse_发布了新的文献求助10
18秒前
whc完成签到,获得积分10
19秒前
19秒前
19秒前
NexusExplorer的应助被ws采纳,获得20
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640